Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer

Via Peters

SAN ANTONIO — A headline-making antibody-drug conjugate (ADC) continued to impress breast cancer specialists by demonstrating activity in tumors with low HER2 expression and in some breast cancers with undetectable HER2. As expected, trastuzumab deruxtecan (T-DXd, Enhertu) showed robust activity in HER2-overexpressing metastatic breast cancer, producing objective responses in 71% […]